Drugs that contain Carbamazepine

1. List of Carnexiv drug patents

CARNEXIV's oppositions filed in EPO
CARNEXIV Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770407 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(5 years from now)

US9629797 LUNDBECK PHARMS LLC Parenteral carbamazepine formulation
Nov, 2028

(5 years from now)

US8410077 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US7635773 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9750822 LUNDBECK PHARMS LLC Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(5 years from now)

US9493582 LUNDBECK PHARMS LLC Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

US11529357 LUNDBECK PHARMS LLC Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
Jan, 2040

(16 years from now)

Do you want to check out CARNEXIV patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Oct 7, 2023

Market Authorisation Date: 07 October, 2016

Treatment: Replacement therapy for oral carbamazepine in adults with partial seizures with complex symptomatology; Replacement therapy for oral carbamazepine in adults with generalized tonic-clonic seizures; Rep...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

CARNEXIV family patents

25

United States

10

Japan

6

China

5

European Union

4

Australia

4

Korea, Republic of

4

Canada

4

Russia

4

Mexico

2

Israel

2

New Zealand

2

Spain

2

Hong Kong

2

Brazil

EA

1

EA

1

Denmark

1

Cyprus

1

Portugal

1

Poland

1

Slovenia

1

South Africa

2. List of Equetro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6977253 VALIDUS PHARMS Methods for the treatment of bipolar disorder using carbamazepine
May, 2024

(11 months from now)

Do you want to check out EQUETRO patents from before 2022?

Market Authorisation Date: 10 December, 2004

Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of EQUETRO before it's patent expiration?
More Information on Dosage

EQUETRO family patents

3

United States

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic